These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2529825)

  • 1. [Zoladex as a depot GnRH agonist in premenopausal metastatic breast cancer].
    Schmid H; Schachner-Wünschmann E; Kaufmann M
    Arch Gynecol Obstet; 1989; 245(1-4):741-3. PubMed ID: 2529825
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
    Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
    Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer--a 5-year experience and further endocrine therapies. Cooperative German Zoladex Study Group.
    Kaufmann M; Jonat W; Schachner-Wünschmann E; Bastert G; Maass H
    Onkologie; 1991 Feb; 14(1):22-4, 26-8, 30. PubMed ID: 1829149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
    Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
    J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women.
    Matta WH; Shaw RW; Burford GD
    Fertil Steril; 1988 Jan; 49(1):163-5. PubMed ID: 2961621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer.
    Walker KJ; Walker RF; Turkes A; Robertson JF; Blamey RW; Griffiths K; Nicholson RI
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):651-4. PubMed ID: 2523808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist.
    Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M
    Anticancer Drugs; 1992 Feb; 3(1):3-8. PubMed ID: 1535804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer.
    Robertson JF; Walker KJ; Nicholson RI; Blamey RW
    Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study).
    Bianco AR; Rosso R; Calabresi F; Fiorentino M; Lopez M; Sismondi PG; Lenti R; Fosser V; De Placido S; Perrone F
    Eur J Gynaecol Oncol; 1991; 12(6):429-37. PubMed ID: 1839730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
    Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
    Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer.
    Walker KJ; Turkes A; Williams MR; Blamey RW; Nicholson RI
    J Endocrinol; 1986 Nov; 111(2):349-53. PubMed ID: 2947964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Goserelin depot in the treatment of premenopausal advanced breast cancer.
    Blamey RW; Jonat W; Kaufmann M; Bianco AR; Namer M
    Eur J Cancer; 1992; 28A(4-5):810-4. PubMed ID: 1388037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of a patient with severe menstrual migraine using the depot LHRH analogue Zoladex.
    Holdaway IM; Parr CE; France J
    Aust N Z J Obstet Gynaecol; 1991 May; 31(2):164-5. PubMed ID: 1834050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical castration with zoladex: a conservative approach to premenopausal breast cancer.
    Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M; Bonadonna G
    Tumori; 1991 Apr; 77(2):145-50. PubMed ID: 1828640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoladex in the treatment of premenopausal metastatic breast cancer patients.
    Kaufmann M
    Horm Res; 1989; 32 Suppl 1():202-5. PubMed ID: 2533150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine effects of goserelin, a new depot luteinising hormone releasing hormone agonist.
    Thomas EJ; Jenkins J; Lenton EA; Cooke ID
    Br Med J (Clin Res Ed); 1986 Nov; 293(6559):1407-8. PubMed ID: 2948607
    [No Abstract]   [Full Text] [Related]  

  • 17. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
    Mahler C; Denis L
    Am J Clin Oncol; 1988; 11 Suppl 2():S127-8. PubMed ID: 2977268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
    Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
    Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women.
    Filicori M; Flamigni C; Cognigni G; Dellai P; Arnone R; Falbo A; Capelli M
    J Clin Endocrinol Metab; 1993 Jul; 77(1):130-3. PubMed ID: 8325935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.